查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1860014

DNA疫苗：全球市場佔有率和排名、總收入和需求預測（2025-2031年）

DNA Vaccines - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 90 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

全球DNA疫苗市場預計在2024年達到53.78億美元，預計到2031年將達到89.75億美元，在預測期（2025-2031年）內以7.7%的複合年成長率成長。

DNA疫苗是利用重組DNA技術將編碼病原體特定抗原的質體或其他DNA載體導入宿主生物體，使宿主細胞能夠轉錄和翻譯這些抗原，進而誘發特異性免疫反應的疫苗。與傳統的去活化疫苗或減毒疫苗相比，DNA疫苗具有設計靈活、生產週期短、安全性較高以及不存在病原體完全傳播風險等優勢。由於其具有快速客製化、大規模生產和相對易於儲存的潛力，DNA疫苗在感染疾病預防、腫瘤免疫治療以及快速應對公共衛生威脅方面展現出巨大的應用前景，並已成為全球生物製藥公司、政府和研究機構關注的重點。

鑑於全球公共衛生需求日益成長、感染疾病病變種頻繁出現、癌症發病率上升以及抗菌素抗藥性蔓延，DNA疫苗正日益被視為下一代疫苗和免疫療法的核心解決方案。各國政府和國際組織已大幅增加針對新冠病毒、瘧疾和登革熱等新興病原體的研究經費，為DNA疫苗計劃提供持續的政策和資金支持。同時，合成生物學、基因合成、質體設計和免疫抗原性最佳化的突破縮短了從實驗室檢驗到臨床階段的時間，並降低了失敗成本。在臨床試驗中，一些DNA疫苗候選產品展現出良好的安全性和免疫反應（包括T細胞反應），提振了市場和投資人的信心。此外，由於病毒性和寄生蟲性疾病對畜牧業和水產養殖業造成了毀滅性損失，獸用疫苗的需求持續成長。 DNA疫苗因其低溫運輸和運輸優勢而備受青睞，使這些市場成為重要的早期商業化基礎。市場估值預測顯示，未來十年DNA疫苗產業將以約6-7%的複合年成長率成長，市場規模將翻倍，從研發到生產和分銷的整個過程都將創造巨大的利潤潛力。

然而，DNA疫苗在普及應用前仍面臨許多挑戰。首先，免疫抗原性。目前，人們對DNA疫苗在人體內的免疫反應強度和持久性仍存在不確定性，尤其與基於蛋白質和病毒載體的疫苗相比。一些處於早期試驗階段的候選疫苗尚未誘發足夠的抗體或持久的T細胞反應。其次，監管核准流程十分嚴格。每個司法管轄區都對安全性、長期影響和基因插入風險提出了嚴格的要求，這可能會延長上市時間並增加成本。第三，成本和生產複雜性都很高，尤其是在質體生產、純化、遞送系統以及儲存和運輸（包括低溫或亞低溫鏈）方面。高標準的GMP設施和嚴格的品管至關重要，因為任何缺陷都可能影響疫苗的穩定性和安全性。第四，市場教育和接受度至關重要。醫療專業人員、患者和公共衛生機構仍處於學習階段，對副作用和長期結果的不確定性可能會導致猶豫不決，從而降低疫苗的普及率。

在下游應用領域，預防性應用（針對感染疾病）仍然是主要需求來源，尤其是在地方性流行地區或現有疫苗供應不足的地區。自新冠疫情爆發以來，初免-加強免疫、加強免疫和異源免疫策略重新激發了人們對DNA疫苗的興趣，使其成為具有高穩定性和快速生產能力的補充工具。治療性應用正在迅速擴展：癌症疫苗、慢性病毒感染疾病疫苗（例如HIV、HBV/HCV）以及寄生蟲和真菌疾病疫苗均處於臨床試驗或早期研究階段。在獸醫學領域，家禽、水產養殖和畜牧業對DNA疫苗的需求強勁，因為它們可以減少疾病損失和抗生素使用，並提高生產力。公共衛生和政府採購機構越來越關注疫苗的全生命週期成本（運輸和儲存基礎設施、劑量、耐久性和廣泛的免疫覆蓋範圍），這進一步增強了DNA疫苗的吸引力，因為它們具有高穩定性、接種週期少和免疫反應廣等優點。

本報告旨在對全球DNA疫苗市場進行全面分析，重點關注總收入、市場佔有率和主要企業的排名，以及按地區/國家、類型和應用對DNA疫苗進行分析。

本報告以2024年為基準年，按銷售收入提供DNA疫苗市場規模、估計值和預測，並包含2020年至2031年的歷史數據和預測數據。我們運用定量和定性分析，幫助讀者制定業務/成長策略，評估市場競爭格局，分析自身在當前市場中的地位，並就DNA疫苗做出明智的商業決策。

市場區隔

公司

  • Merck
  • GSK
  • Sanofi
  • Zoties
  • Elanco
  • Boehringer-Ingelheim
  • Indian Immunologicals
  • Plumbline Life Sciences

按類型分類的細分市場

  • 重組蛋白疫苗
  • 基因疫苗

應用領域

  • 人類
  • 動物

按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 韓國
    • 東南亞
    • 印度
    • 澳洲
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 荷蘭
    • 北歐國家
    • 其他歐洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中東和非洲
    • 土耳其
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他中東和非洲地區

The global market for DNA Vaccines was estimated to be worth US$ 5378 million in 2024 and is forecast to a readjusted size of US$ 8975 million by 2031 with a CAGR of 7.7% during the forecast period 2025-2031.

DNA vaccines are vaccines that use recombinant DNA technology, introducing plasmids or other DNA vectors encoding specific antigens of a pathogen into the host organism, where host cells transcribe and translate the antigen, thus eliciting a specific immune response. Compared to traditional inactivated or attenuated vaccines, DNA vaccines offer flexibility in design, shorter production cycles, relatively high safety, and no risk of transmission of the complete pathogen. They are particularly promising in prevention of infectious diseases, tumor immunotherapy, and rapid response to public health threats, thanks to their capability for rapid customization, large-scale production, and comparatively easier storage, making them a key focus for global biopharma companies, governments, and research institutions.

Amid growing global public health needs, frequent emergence of infectious disease variants, rising cancer incidence, and escalating antimicrobial resistance, DNA vaccines are increasingly viewed as core next-generation vaccine and immunotherapy solutions. Governments and international agencies have significantly increased funding for research targeting emerging pathogens (such as coronaviruses, malaria, dengue etc.), thereby providing continuous policy and financial support for DNA vaccine projects. At the same time, leaps in synthetic biology, gene synthesis, plasmid design and immunogenicity optimization have shortened timelines from lab validation to clinical stages, reducing failure costs. In clinical trials, multiple DNA vaccine candidates have shown positive safety profiles and immune responses (including T cell responses), boosting the confidence of markets and investors. Moreover, demand in the animal health / veterinary vaccine sector continues to accelerate, as viral and parasitic diseases exact heavy losses in livestock/aquaculture, and DNA vaccines' advantages in cold chain and transport make them particularly appealing, making those markets important early commercial footholds. Market valuation forecasts suggest the DNA vaccine industry will grow at a roughly 6-7% compound annual growth rate over the next decade, with market size likely to double, yielding large profit potential along the entire chain-from R&D through manufacturing and distribution.

However, for DNA vaccines to become mainstream there are substantial challenges. First is immunogenicity: the strength and durability of immune responses in humans, especially relative to protein-based or viral vector vaccines, remain uncertain; some candidates in early trials have not elicited sufficiently high neutralizing antibodies or lasting T cell responses. Second, regulatory approval processes are stringent; different jurisdictions impose very cautious requirements about safety, long-term effects, gene insertion risks, etc., which may lengthen time to market and raise costs. Third, cost and production complexity are high, particularly in plasmid production, purification, delivery systems, and storage/transport (including cold or semi-cold chain) steps. High standard GMP facilities and rigorous quality control are essential; any lapse can impact stability and safety. Fourth, market education and acceptance: medical practitioners, patients, and public health bodies are still learning; uncertainty around side effects or long-term outcomes may fuel hesitancy and reduce uptake.

Downstream, preventive applications (for infectious diseases) remain the dominant demand, especially in regions with frequent outbreaks or under-served by existing vaccine supply. Post-COVID-19, prime-boost regimens, booster shots, and heterologous immunization strategies are giving DNA vaccines renewed interest as stable, rapidly producible complements. Therapeutic applications are growing fast: cancer vaccines, chronic viral infections (e.g. HIV, HBV/HCV), parasitic/fungal disease vaccines are under clinical or early stage research. In the veterinary sector, demand is robust in poultry, aquaculture, and livestock for DNA vaccines that reduce disease losses, antibiotic use, and enhance yield. Public health bodies and government purchasers increasingly focus on total life-cycle cost: transportation & storage infrastructure, dose volume, durability, breadth of immune coverage-all of which amplify the attractiveness of DNA vaccines that are stable, require fewer doses, and have broad immune responses.

This report aims to provide a comprehensive presentation of the global market for DNA Vaccines, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of DNA Vaccines by region & country, by Type, and by Application.

The DNA Vaccines market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding DNA Vaccines.

Market Segmentation

By Company

  • Merck
  • GSK
  • Sanofi
  • Zoties
  • Elanco
  • Boehringer-Ingelheim
  • Indian Immunologicals
  • Plumbline Life Sciences

Segment by Type

  • Recombinant Protein Vaccine
  • Gene-Based Vaccine

Segment by Application

  • Human
  • Animal

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of DNA Vaccines company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of DNA Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of DNA Vaccines in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 DNA Vaccines Product Introduction
  • 1.2 Global DNA Vaccines Market Size Forecast (2020-2031)
  • 1.3 DNA Vaccines Market Trends & Drivers
    • 1.3.1 DNA Vaccines Industry Trends
    • 1.3.2 DNA Vaccines Market Drivers & Opportunity
    • 1.3.3 DNA Vaccines Market Challenges
    • 1.3.4 DNA Vaccines Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global DNA Vaccines Players Revenue Ranking (2024)
  • 2.2 Global DNA Vaccines Revenue by Company (2020-2025)
  • 2.3 Key Companies DNA Vaccines Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies DNA Vaccines Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of DNA Vaccines
  • 2.6 DNA Vaccines Market Competitive Analysis
    • 2.6.1 DNA Vaccines Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by DNA Vaccines Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in DNA Vaccines as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Recombinant Protein Vaccine
    • 3.1.2 Gene-Based Vaccine
  • 3.2 Global DNA Vaccines Sales Value by Type
    • 3.2.1 Global DNA Vaccines Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global DNA Vaccines Sales Value, by Type (2020-2031)
    • 3.2.3 Global DNA Vaccines Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Human
    • 4.1.2 Animal
  • 4.2 Global DNA Vaccines Sales Value by Application
    • 4.2.1 Global DNA Vaccines Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global DNA Vaccines Sales Value, by Application (2020-2031)
    • 4.2.3 Global DNA Vaccines Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global DNA Vaccines Sales Value by Region
    • 5.1.1 Global DNA Vaccines Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global DNA Vaccines Sales Value by Region (2020-2025)
    • 5.1.3 Global DNA Vaccines Sales Value by Region (2026-2031)
    • 5.1.4 Global DNA Vaccines Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America DNA Vaccines Sales Value, 2020-2031
    • 5.2.2 North America DNA Vaccines Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe DNA Vaccines Sales Value, 2020-2031
    • 5.3.2 Europe DNA Vaccines Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific DNA Vaccines Sales Value, 2020-2031
    • 5.4.2 Asia Pacific DNA Vaccines Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America DNA Vaccines Sales Value, 2020-2031
    • 5.5.2 South America DNA Vaccines Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa DNA Vaccines Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa DNA Vaccines Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions DNA Vaccines Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions DNA Vaccines Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States DNA Vaccines Sales Value, 2020-2031
    • 6.3.2 United States DNA Vaccines Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States DNA Vaccines Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe DNA Vaccines Sales Value, 2020-2031
    • 6.4.2 Europe DNA Vaccines Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe DNA Vaccines Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China DNA Vaccines Sales Value, 2020-2031
    • 6.5.2 China DNA Vaccines Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China DNA Vaccines Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan DNA Vaccines Sales Value, 2020-2031
    • 6.6.2 Japan DNA Vaccines Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan DNA Vaccines Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea DNA Vaccines Sales Value, 2020-2031
    • 6.7.2 South Korea DNA Vaccines Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea DNA Vaccines Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia DNA Vaccines Sales Value, 2020-2031
    • 6.8.2 Southeast Asia DNA Vaccines Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia DNA Vaccines Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India DNA Vaccines Sales Value, 2020-2031
    • 6.9.2 India DNA Vaccines Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India DNA Vaccines Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Merck
    • 7.1.1 Merck Profile
    • 7.1.2 Merck Main Business
    • 7.1.3 Merck DNA Vaccines Products, Services and Solutions
    • 7.1.4 Merck DNA Vaccines Revenue (US$ Million) & (2020-2025)
    • 7.1.5 Merck Recent Developments
  • 7.2 GSK
    • 7.2.1 GSK Profile
    • 7.2.2 GSK Main Business
    • 7.2.3 GSK DNA Vaccines Products, Services and Solutions
    • 7.2.4 GSK DNA Vaccines Revenue (US$ Million) & (2020-2025)
    • 7.2.5 GSK Recent Developments
  • 7.3 Sanofi
    • 7.3.1 Sanofi Profile
    • 7.3.2 Sanofi Main Business
    • 7.3.3 Sanofi DNA Vaccines Products, Services and Solutions
    • 7.3.4 Sanofi DNA Vaccines Revenue (US$ Million) & (2020-2025)
    • 7.3.5 Sanofi Recent Developments
  • 7.4 Zoties
    • 7.4.1 Zoties Profile
    • 7.4.2 Zoties Main Business
    • 7.4.3 Zoties DNA Vaccines Products, Services and Solutions
    • 7.4.4 Zoties DNA Vaccines Revenue (US$ Million) & (2020-2025)
    • 7.4.5 Zoties Recent Developments
  • 7.5 Elanco
    • 7.5.1 Elanco Profile
    • 7.5.2 Elanco Main Business
    • 7.5.3 Elanco DNA Vaccines Products, Services and Solutions
    • 7.5.4 Elanco DNA Vaccines Revenue (US$ Million) & (2020-2025)
    • 7.5.5 Elanco Recent Developments
  • 7.6 Boehringer-Ingelheim
    • 7.6.1 Boehringer-Ingelheim Profile
    • 7.6.2 Boehringer-Ingelheim Main Business
    • 7.6.3 Boehringer-Ingelheim DNA Vaccines Products, Services and Solutions
    • 7.6.4 Boehringer-Ingelheim DNA Vaccines Revenue (US$ Million) & (2020-2025)
    • 7.6.5 Boehringer-Ingelheim Recent Developments
  • 7.7 Indian Immunologicals
    • 7.7.1 Indian Immunologicals Profile
    • 7.7.2 Indian Immunologicals Main Business
    • 7.7.3 Indian Immunologicals DNA Vaccines Products, Services and Solutions
    • 7.7.4 Indian Immunologicals DNA Vaccines Revenue (US$ Million) & (2020-2025)
    • 7.7.5 Indian Immunologicals Recent Developments
  • 7.8 Plumbline Life Sciences
    • 7.8.1 Plumbline Life Sciences Profile
    • 7.8.2 Plumbline Life Sciences Main Business
    • 7.8.3 Plumbline Life Sciences DNA Vaccines Products, Services and Solutions
    • 7.8.4 Plumbline Life Sciences DNA Vaccines Revenue (US$ Million) & (2020-2025)
    • 7.8.5 Plumbline Life Sciences Recent Developments

8 Industry Chain Analysis

  • 8.1 DNA Vaccines Industrial Chain
  • 8.2 DNA Vaccines Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 DNA Vaccines Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 DNA Vaccines Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. DNA Vaccines Market Trends
  • Table 2. DNA Vaccines Market Drivers & Opportunity
  • Table 3. DNA Vaccines Market Challenges
  • Table 4. DNA Vaccines Market Restraints
  • Table 5. Global DNA Vaccines Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global DNA Vaccines Revenue Market Share by Company (2020-2025)
  • Table 7. Key Companies DNA Vaccines Manufacturing Base Distribution and Headquarters
  • Table 8. Key Companies DNA Vaccines Product Type
  • Table 9. Key Companies Time to Begin Mass Production of DNA Vaccines
  • Table 10. Global DNA Vaccines Companies Market Concentration Ratio (CR5 and HHI)
  • Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in DNA Vaccines as of 2024)
  • Table 12. Mergers & Acquisitions, Expansion Plans
  • Table 13. Global DNA Vaccines Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 14. Global DNA Vaccines Sales Value by Type (2020-2025) & (US$ Million)
  • Table 15. Global DNA Vaccines Sales Value by Type (2026-2031) & (US$ Million)
  • Table 16. Global DNA Vaccines Sales Market Share in Value by Type (2020-2025)
  • Table 17. Global DNA Vaccines Sales Market Share in Value by Type (2026-2031)
  • Table 18. Global DNA Vaccines Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 19. Global DNA Vaccines Sales Value by Application (2020-2025) & (US$ Million)
  • Table 20. Global DNA Vaccines Sales Value by Application (2026-2031) & (US$ Million)
  • Table 21. Global DNA Vaccines Sales Market Share in Value by Application (2020-2025)
  • Table 22. Global DNA Vaccines Sales Market Share in Value by Application (2026-2031)
  • Table 23. Global DNA Vaccines Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 24. Global DNA Vaccines Sales Value by Region (2020-2025) & (US$ Million)
  • Table 25. Global DNA Vaccines Sales Value by Region (2026-2031) & (US$ Million)
  • Table 26. Global DNA Vaccines Sales Value by Region (2020-2025) & (%)
  • Table 27. Global DNA Vaccines Sales Value by Region (2026-2031) & (%)
  • Table 28. Key Countries/Regions DNA Vaccines Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 29. Key Countries/Regions DNA Vaccines Sales Value, (2020-2025) & (US$ Million)
  • Table 30. Key Countries/Regions DNA Vaccines Sales Value, (2026-2031) & (US$ Million)
  • Table 31. Merck Basic Information List
  • Table 32. Merck Description and Business Overview
  • Table 33. Merck DNA Vaccines Products, Services and Solutions
  • Table 34. Revenue (US$ Million) in DNA Vaccines Business of Merck (2020-2025)
  • Table 35. Merck Recent Developments
  • Table 36. GSK Basic Information List
  • Table 37. GSK Description and Business Overview
  • Table 38. GSK DNA Vaccines Products, Services and Solutions
  • Table 39. Revenue (US$ Million) in DNA Vaccines Business of GSK (2020-2025)
  • Table 40. GSK Recent Developments
  • Table 41. Sanofi Basic Information List
  • Table 42. Sanofi Description and Business Overview
  • Table 43. Sanofi DNA Vaccines Products, Services and Solutions
  • Table 44. Revenue (US$ Million) in DNA Vaccines Business of Sanofi (2020-2025)
  • Table 45. Sanofi Recent Developments
  • Table 46. Zoties Basic Information List
  • Table 47. Zoties Description and Business Overview
  • Table 48. Zoties DNA Vaccines Products, Services and Solutions
  • Table 49. Revenue (US$ Million) in DNA Vaccines Business of Zoties (2020-2025)
  • Table 50. Zoties Recent Developments
  • Table 51. Elanco Basic Information List
  • Table 52. Elanco Description and Business Overview
  • Table 53. Elanco DNA Vaccines Products, Services and Solutions
  • Table 54. Revenue (US$ Million) in DNA Vaccines Business of Elanco (2020-2025)
  • Table 55. Elanco Recent Developments
  • Table 56. Boehringer-Ingelheim Basic Information List
  • Table 57. Boehringer-Ingelheim Description and Business Overview
  • Table 58. Boehringer-Ingelheim DNA Vaccines Products, Services and Solutions
  • Table 59. Revenue (US$ Million) in DNA Vaccines Business of Boehringer-Ingelheim (2020-2025)
  • Table 60. Boehringer-Ingelheim Recent Developments
  • Table 61. Indian Immunologicals Basic Information List
  • Table 62. Indian Immunologicals Description and Business Overview
  • Table 63. Indian Immunologicals DNA Vaccines Products, Services and Solutions
  • Table 64. Revenue (US$ Million) in DNA Vaccines Business of Indian Immunologicals (2020-2025)
  • Table 65. Indian Immunologicals Recent Developments
  • Table 66. Plumbline Life Sciences Basic Information List
  • Table 67. Plumbline Life Sciences Description and Business Overview
  • Table 68. Plumbline Life Sciences DNA Vaccines Products, Services and Solutions
  • Table 69. Revenue (US$ Million) in DNA Vaccines Business of Plumbline Life Sciences (2020-2025)
  • Table 70. Plumbline Life Sciences Recent Developments
  • Table 71. Key Raw Materials Lists
  • Table 72. Raw Materials Key Suppliers Lists
  • Table 73. DNA Vaccines Downstream Customers
  • Table 74. DNA Vaccines Distributors List
  • Table 75. Research Programs/Design for This Report
  • Table 76. Key Data Information from Secondary Sources
  • Table 77. Key Data Information from Primary Sources

List of Figures

  • Figure 1. DNA Vaccines Product Picture
  • Figure 2. Global DNA Vaccines Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global DNA Vaccines Sales Value (2020-2031) & (US$ Million)
  • Figure 4. DNA Vaccines Report Years Considered
  • Figure 5. Global DNA Vaccines Players Revenue Ranking (2024) & (US$ Million)
  • Figure 6. The 5 and 10 Largest Companies in the World: Market Share by DNA Vaccines Revenue in 2024
  • Figure 7. DNA Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 8. Recombinant Protein Vaccine Picture
  • Figure 9. Gene-Based Vaccine Picture
  • Figure 10. Global DNA Vaccines Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 11. Global DNA Vaccines Sales Value Market Share by Type, 2024 & 2031
  • Figure 12. Product Picture of Human
  • Figure 13. Product Picture of Animal
  • Figure 14. Global DNA Vaccines Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 15. Global DNA Vaccines Sales Value Market Share by Application, 2024 & 2031
  • Figure 16. North America DNA Vaccines Sales Value (2020-2031) & (US$ Million)
  • Figure 17. North America DNA Vaccines Sales Value by Country (%), 2024 VS 2031
  • Figure 18. Europe DNA Vaccines Sales Value, (2020-2031) & (US$ Million)
  • Figure 19. Europe DNA Vaccines Sales Value by Country (%), 2024 VS 2031
  • Figure 20. Asia Pacific DNA Vaccines Sales Value, (2020-2031) & (US$ Million)
  • Figure 21. Asia Pacific DNA Vaccines Sales Value by Region (%), 2024 VS 2031
  • Figure 22. South America DNA Vaccines Sales Value, (2020-2031) & (US$ Million)
  • Figure 23. South America DNA Vaccines Sales Value by Country (%), 2024 VS 2031
  • Figure 24. Middle East & Africa DNA Vaccines Sales Value, (2020-2031) & (US$ Million)
  • Figure 25. Middle East & Africa DNA Vaccines Sales Value by Country (%), 2024 VS 2031
  • Figure 26. Key Countries/Regions DNA Vaccines Sales Value (%), (2020-2031)
  • Figure 27. United States DNA Vaccines Sales Value, (2020-2031) & (US$ Million)
  • Figure 28. United States DNA Vaccines Sales Value by Type (%), 2024 VS 2031
  • Figure 29. United States DNA Vaccines Sales Value by Application (%), 2024 VS 2031
  • Figure 30. Europe DNA Vaccines Sales Value, (2020-2031) & (US$ Million)
  • Figure 31. Europe DNA Vaccines Sales Value by Type (%), 2024 VS 2031
  • Figure 32. Europe DNA Vaccines Sales Value by Application (%), 2024 VS 2031
  • Figure 33. China DNA Vaccines Sales Value, (2020-2031) & (US$ Million)
  • Figure 34. China DNA Vaccines Sales Value by Type (%), 2024 VS 2031
  • Figure 35. China DNA Vaccines Sales Value by Application (%), 2024 VS 2031
  • Figure 36. Japan DNA Vaccines Sales Value, (2020-2031) & (US$ Million)
  • Figure 37. Japan DNA Vaccines Sales Value by Type (%), 2024 VS 2031
  • Figure 38. Japan DNA Vaccines Sales Value by Application (%), 2024 VS 2031
  • Figure 39. South Korea DNA Vaccines Sales Value, (2020-2031) & (US$ Million)
  • Figure 40. South Korea DNA Vaccines Sales Value by Type (%), 2024 VS 2031
  • Figure 41. South Korea DNA Vaccines Sales Value by Application (%), 2024 VS 2031
  • Figure 42. Southeast Asia DNA Vaccines Sales Value, (2020-2031) & (US$ Million)
  • Figure 43. Southeast Asia DNA Vaccines Sales Value by Type (%), 2024 VS 2031
  • Figure 44. Southeast Asia DNA Vaccines Sales Value by Application (%), 2024 VS 2031
  • Figure 45. India DNA Vaccines Sales Value, (2020-2031) & (US$ Million)
  • Figure 46. India DNA Vaccines Sales Value by Type (%), 2024 VS 2031
  • Figure 47. India DNA Vaccines Sales Value by Application (%), 2024 VS 2031
  • Figure 48. DNA Vaccines Industrial Chain
  • Figure 49. DNA Vaccines Manufacturing Cost Structure
  • Figure 50. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 51. Bottom-up and Top-down Approaches for This Report
  • Figure 52. Data Triangulation
  • Figure 53. Key Executives Interviewed